Evidence map›Paper›PMID 28566213›Full record

ArticleThe Lancet. Global health2017

Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study.

Oliver J Brady, Hannah C Slater, Peter Pemberton-Ross, Edward Wenger, Richard J Maude, Azra C Ghani, Melissa A Penny, Jaline Gerardin, Lisa J White, Nakul Chitnis and 7 more

Open access · goldAbstract read
In one paragraph

Article in The Lancet. Global health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 4 pooled it
15.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 4 syntheses or guidelines pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Mass drug administration for malaria.The Cochrane database of systematic reviews · 2021
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Dihydroartemisinin-Piperaquine Chemoprevention and Malaria Incidence After Severe Flooding: Evaluation of a Pragmatic Intervention in Rural Uganda.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial
  8. Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 5 countries.

Oliver J BradyCentre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, and Malaria Modelling Consortium, London School of Hygiene & Tropical Medicine, London, UK.
Hannah C SlaterMRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College, London, UK.
Peter Pemberton-RossSwiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.
Edward WengerInstitute for Disease Modeling, Bellevue, WA, USA.
Richard J MaudeMahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK; Harvard TH Chan School of Public Health, Harvard University, Boston, MA, USA.
Azra C GhaniMRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College, London, UK.
Melissa A PennySwiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.
Jaline GerardinInstitute for Disease Modeling, Bellevue, WA, USA.
Lisa J WhiteMahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
Nakul ChitnisSwiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.
Ricardo AguasMahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
Simon I HayOxford Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK; Malaria Modelling Consortium, University of Washington, Seattle, WA, USA; Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
David L SmithInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Erin M StuckeyMalaria Modelling Consortium, Bill & Melinda Gates Foundation, Seattle, WA, USA.
Emelda A OkiroMalaria Modelling Consortium, Bill & Melinda Gates Foundation, Seattle, WA, USA; Kemri Wellcome Trust Research Programme, Nairobi, Kenya.
Thomas A SmithSwiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.
Lucy C OkellMRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College, London, UK. Electronic address: l.okell@imperial.ac.uk.
Imperial College London · GBInstitute for Disease Modeling · USSwiss Tropical and Public Health Institute · CHUniversity of Basel · CHUniversity of Oxford · GBBill & Melinda Gates Foundation · USInstitute for Health Metrics and Evaluation · USKenya Medical Research Institute · KELondon School of Hygiene & Tropical Medicine · GBMahidol Oxford Tropical Medicine Research Unit · THUniversity of Washington · US

Funding

Medical Research Council G1002387Wellcome Trust 095066
6 · The paper itself

Abstract

backgroundMass drug administration for elimination of Plasmodium falciparum malaria is recommended by WHO in some settings. We used consensus modelling to understand how to optimise the effects of mass drug administration in areas with low malaria transmission.

methodsWe collaborated with researchers doing field trials to establish a standard intervention scenario and standard transmission setting, and we input these parameters into four previously published models. We then varied the number of rounds of mass drug administration, coverage, duration, timing, importation of infection, and pre-administration transmission levels. The outcome of interest was the percentage reduction in annual mean prevalence of P falciparum parasite rate as measured by PCR in the third year after the final round of mass drug administration.

findingsThe models predicted differing magnitude of the effects of mass drug administration, but consensus answers were reached for several factors. Mass drug administration was predicted to reduce transmission over a longer timescale than accounted for by the prophylactic effect alone. Percentage reduction in transmission was predicted to be higher and last longer at lower baseline transmission levels. Reduction in transmission resulting from mass drug administration was predicted to be temporary, and in the absence of scale-up of other interventions, such as vector control, transmission would return to pre-administration levels. The proportion of the population treated in a year was a key determinant of simulated effectiveness, irrespective of whether people are treated through high coverage in a single round or new individuals are reached by implementation of several rounds. Mass drug administration was predicted to be more effective if continued over 2 years rather than 1 year, and if done at the time of year when transmission is lowest.

interpretationMass drug administration has the potential to reduce transmission for a limited time, but is not an effective replacement for existing vector control. Unless elimination is achieved, mass drug administration has to be repeated regularly for sustained effect.

fundingBill & Melinda Gates Foundation.

Indexed as

Models, TheoreticalAntimalarialsArtemisininsConsensusHumansMalaria, FalciparumMass Drug AdministrationPlasmodium falciparumPrevalenceAntimalarialsArtemisinins

Identifiers

PMID28566213
PMCPMC5469936
OpenAlexW2617508148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.